221 related articles for article (PubMed ID: 10654629)
1. Pharmacodynamic modeling of risk factors for ciprofloxacin resistance in Pseudomonas aeruginosa.
Hyatt JM; Schentag JJ
Infect Control Hosp Epidemiol; 2000 Jan; 21(1 Suppl):S9-11. PubMed ID: 10654629
[TBL] [Abstract][Full Text] [Related]
2. Potential role of pharmacokinetics, pharmacodynamics, and computerized databases in controlling bacterial resistance.
Hyatt JM; Schentag JJ
Infect Control Hosp Epidemiol; 2000 Jan; 21(1 Suppl):S18-21. PubMed ID: 10654631
[TBL] [Abstract][Full Text] [Related]
3. Predictors of bacterial resistance using in vitro dynamic models: area under the concentration-time curve related to either the minimum inhibitory or mutant prevention antibiotic concentration.
Strukova EN; Portnoy YA; Zinner SH; Firsov AA
J Antimicrob Chemother; 2016 Mar; 71(3):678-84. PubMed ID: 26626718
[TBL] [Abstract][Full Text] [Related]
4. Ciprofloxacin-resistant Pseudomonas keratitis.
Garg P; Sharma S; Rao GN
Ophthalmology; 1999 Jul; 106(7):1319-23. PubMed ID: 10406614
[TBL] [Abstract][Full Text] [Related]
5. Effect of a program to reduce hospital ciprofloxacin use on nosocomial Pseudomonas aeruginosa susceptibility to quinolones and other antimicrobial agents.
Cook PP; Das TD; Gooch M; Catrou PG
Infect Control Hosp Epidemiol; 2008 Aug; 29(8):716-22. PubMed ID: 18590455
[TBL] [Abstract][Full Text] [Related]
6. Decreased resistance of Pseudomonas aeruginosa with restriction of ciprofloxacin in a large teaching hospital's intensive care and intermediate care units.
Lewis GJ; Fang X; Gooch M; Cook PP
Infect Control Hosp Epidemiol; 2012 Apr; 33(4):368-73. PubMed ID: 22418632
[TBL] [Abstract][Full Text] [Related]
7. Review of resistance of ocular isolates of Pseudomonas aeruginosa and staphylococci from keratitis to ciprofloxacin, gentamicin and cephalosporins.
Willcox MD
Clin Exp Optom; 2011 Mar; 94(2):161-8. PubMed ID: 21083760
[TBL] [Abstract][Full Text] [Related]
8. Bacterial antibiotic resistance studies using in vitro dynamic models: Population analysis vs. susceptibility testing as endpoints of mutant enrichment.
Firsov AA; Strukova EN; Portnoy YA; Shlykova DS; Zinner SH
Int J Antimicrob Agents; 2015 Sep; 46(3):313-8. PubMed ID: 26297633
[TBL] [Abstract][Full Text] [Related]
9. Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.
Rees VE; Yadav R; Rogers KE; Bulitta JB; Wirth V; Oliver A; Boyce JD; Peleg AY; Nation RL; Landersdorfer CB
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30104278
[TBL] [Abstract][Full Text] [Related]
10. A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa.
Rhee MK; Kowalski RP; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ
Am J Ophthalmol; 2004 Aug; 138(2):226-30. PubMed ID: 15289131
[TBL] [Abstract][Full Text] [Related]
11. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy.
Riou M; Carbonnelle S; Avrain L; Mesaros N; Pirnay JP; Bilocq F; De Vos D; Simon A; Piérard D; Jacobs F; Dediste A; Tulkens PM; Van Bambeke F; Glupczynski Y
Int J Antimicrob Agents; 2010 Dec; 36(6):513-22. PubMed ID: 20926262
[TBL] [Abstract][Full Text] [Related]
12. Concentration-resistance relationships with Pseudomonas aeruginosa exposed to doripenem and ciprofloxacin in an in vitro model.
Zinner SH; Gilbert D; Greer K; Portnoy YA; Firsov AA
J Antimicrob Chemother; 2013 Apr; 68(4):881-7. PubMed ID: 23175594
[TBL] [Abstract][Full Text] [Related]
13. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
Lee YJ; Liu HY; Lin YC; Sun KL; Chun CL; Hsueh PR
Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
[TBL] [Abstract][Full Text] [Related]
14. Efflux pump genes and antimicrobial resistance of Pseudomonas aeruginosa strains isolated from lower respiratory tract infections acquired in an intensive care unit.
Ozer B; Duran N; Onlen Y; Savas L
J Antibiot (Tokyo); 2012 Jan; 65(1):9-13. PubMed ID: 22086166
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa.
Maciá MD; Borrell N; Segura M; Gómez C; Pérez JL; Oliver A
Antimicrob Agents Chemother; 2006 Mar; 50(3):975-83. PubMed ID: 16495260
[TBL] [Abstract][Full Text] [Related]
16. Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance.
Lodise TP; Miller CD; Graves J; Furuno JP; McGregor JC; Lomaestro B; Graffunder E; McNutt LA
Antimicrob Agents Chemother; 2007 Feb; 51(2):417-22. PubMed ID: 17158943
[TBL] [Abstract][Full Text] [Related]
17. Emerging ciprofloxacin-resistant Pseudomonas aeruginosa.
Chaudhry NA; Flynn HW; Murray TG; Tabandeh H; Mello MO; Miller D
Am J Ophthalmol; 1999 Oct; 128(4):509-10. PubMed ID: 10577596
[TBL] [Abstract][Full Text] [Related]
18. Emergence of ciprofloxacin-resistant pseudomonas in chronic suppurative otitis media.
Jang CH; Park SY
Clin Otolaryngol Allied Sci; 2004 Aug; 29(4):321-3. PubMed ID: 15270816
[TBL] [Abstract][Full Text] [Related]
19. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009.
Master RN; Clark RB; Karlowsky JA; Ramirez J; Bordon JM
Int J Antimicrob Agents; 2011 Oct; 38(4):291-5. PubMed ID: 21737249
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
